1. MiR-153-5p Enhances the Sensitivity of Triple-Negative Breast Cancer Cells to Paclitaxel by Inducing G2M Phase Arrest


    Yang Wang et al, 2020, OncoTargets and Therapy CrossRef
  2. Carrier-Free Nanoparticles via Coassembly of Paclitaxel and Gambogic Acid with Folate-Functionalized Albumin for Targeted Tumor Treatment
    Fanchao Meng et al, 2024, ACS Applied Nano Materials CrossRef
  3. Immune Effect of Active Components of Traditional Chinese Medicine on Triple-Negative Breast Cancer
    Wenjie Zhao et al, 2021, Frontiers in Pharmacology CrossRef
  4. Targeted Chinese Medicine Delivery by A New Family of Biodegradable Pseudo-Protein Nanoparticles for Treating Triple-Negative Breast Cancer: In Vitro and In Vivo Study
    Hiu Yee Kwan et al, 2021, Frontiers in Oncology CrossRef
  5. Therapeutic effect and metabolic fingerprinting of triple-negative breast cancer cells following exposure to a novel pH-responsive, gambogic acid-loaded micelle
    Mengting Da et al, 2024, Nanotechnology CrossRef
  6. Unveiling the Potency of Phyto-Constituents to Target TNBC: Mechanism to Therapeutics
    Sreekumar Usha Devi Aiswarya et al, 2023, Therapeutic Drug Targets and Phytomedicine For Triple Negative Breast Cancer CrossRef
  7. Resistance to Intervention: Paclitaxel in Breast Cancer
    Vipin Mohan Dan et al, 2021, Mini-Reviews in Medicinal Chemistry CrossRef
  8. MiR-1275 Targeting SPARC Promotes Gambogic Acid-Induced Inhibition of Gastric Cancer
    Ang Cai et al, 2023, Biochemical Genetics CrossRef
  9. Herbal Medicine: Prejudice to Realm of Reality Against TNBC
    Balachandran S. Vinod et al, 2023, Therapeutic Drug Targets and Phytomedicine For Triple Negative Breast Cancer CrossRef
  10. Gambogic Acid Lysinate-induced Cervical Cancer SiHa Cells Apoptosis in vitro and in vivo
    Jie Niu et al, 2023, Anti-Cancer Agents in Medicinal Chemistry CrossRef